Joerg Bojunga
Overview
Explore the profile of Joerg Bojunga including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
41
Citations
1663
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Michael F, Feldmann C, Erasmus H, Kubesch A, Goerguelue E, Knabe M, et al.
Ultraschall Med
. 2024 Sep;
PMID: 39222928
Before removal of retained pancreatic stents placed during endoscopic retrograde cholangiopancreatography to avoid post-ERCP pancreatitis, imaging is recommended. The aim of the present study was to evaluate a new ultrasound-based...
2.
Trimboli P, Bojunga J, Deandrea M, Frasca F, Imperiale A, Leoncini A, et al.
Endocrine
. 2024 Jun;
86(1):124-126.
PMID: 38900357
No abstract available.
3.
Trimboli P, Bojunga J, Deandrea M, Frasca F, Imperiale A, Leoncini A, et al.
Endocrine
. 2024 Apr;
85(3):1035-1040.
PMID: 38625504
Thyroid nodules (TNs) are a common entity, with the majority being benign. Therefore, employing an accurate rule-out strategy in clinical practice is essential. In the thyroid field, the current era...
4.
Bojunga J, Trimboli P
Rev Endocr Metab Disord
. 2023 Nov;
25(1):161-173.
PMID: 37946091
Ultrasound (US) of the thyroid has been used as a diagnostic tool since the late 1960s. US is the most important imaging tool for diagnosing thyroid disease. In the majority...
5.
Meyer G, Gruendl M, Chifu I, Hahner S, Werner J, Weiss J, et al.
J Clin Med
. 2023 Oct;
12(19).
PMID: 37835036
Glucocorticoid excess is a known risk factor for non-alcoholic fatty liver disease (NAFLD). Our objective was to analyse the impact of glucocorticoid replacement therapy on the development of NAFLD and...
6.
Koehler V, Achterfeld J, Sandner N, Koch C, Wiegmann J, Ivanyi P, et al.
J Cancer Res Clin Oncol
. 2023 Aug;
149(15):14035-14043.
PMID: 37548775
Purpose: Pathogenic fusion events involving neurotrophic receptor tyrosine kinase (NTRK) have been described in ~ 2% of differentiated thyroid cancer (DTC). The selective tropomyosin receptor kinase (TRK) inhibitors entrectinib and...
7.
Remde H, Schmidt-Pennington L, Reuter M, Landwehr L, Jensen M, Lahner H, et al.
Eur J Endocrinol
. 2023 Jun;
188(6):485-493.
PMID: 37260092
Objective: Clinical trials with immune checkpoint inhibitors (ICI) in adrenocortical carcinoma (ACC) have yielded contradictory results. We aimed to evaluate treatment response and safety of ICI in ACC in a...
8.
Koch C, Bambey C, Filmann N, Stanke M, Waidmann O, Husmann G, et al.
J Clin Med
. 2022 May;
11(9).
PMID: 35566487
Introduction: Scarce data exist for therapy regimens other than somatostatin analogues (SSA) and peptide receptor radiotherapy (PRRT) for siNET. We analyzed real world data for differences in survival according to...
9.
Hunyady P, Herrmann E, Bojunga J, Friedrich-Rust M, Pathil A, Zeuzem S, et al.
Eur J Gastroenterol Hepatol
. 2022 Apr;
34(7):801-806.
PMID: 35482907
Objectives: The diagnostic value of liver biopsy in patients with acute liver injury or acute liver failure (ALI/ALF) was investigated. Methods: Data from the initial event and follow-up visits were...
10.
Gorgulu E, Gu W, Trebicka J, Mucke V, Muecke M, Friedrich-Rust M, et al.
Gut
. 2022 Apr;
71(5):1036-1038.
PMID: 35396231
No abstract available.